How to Use Juvelook: What Practitioners Need to Know

What Juvelook Is — and Why It Cannot Be Used at Home

Juvelook is an injectable medical device manufactured by VAIM Global Inc. (Seoul, South Korea). Each vial contains a lyophilized (freeze-dried) powder composed of PDLLA (poly-D,L-lactic acid, 42.5 mg) and non-crosslinked hyaluronic acid (7.5 mg). It is classified as an MFDS Class IV injectable medical device in Korea and carries CE certification in Europe.

The “lyophilized” designation means the product is supplied as a dry powder that must be reconstituted — mixed with sterile saline — before it can be injected. This is not optional: the dry powder cannot be injected directly, and it cannot be applied topically. The reconstitution and injection steps require sterile technique, medical-grade supplies, and professional training.

Juvelook is not a cream, serum, or dermaroller treatment. It is not available over the counter. It is not designed for consumer self-use. Any website or social media post describing Juvelook as a topical product or a DIY treatment is providing incorrect information. The product works by introducing PDLLA microparticles into the dermis through injection — a procedure that only a qualified medical professional should perform.

(VAIM has separately launched a Juvelook-branded topical skincare line. That is a different product category — cosmetic skincare — and should not be confused with the injectable medical device discussed in this article.)

Before Using Juvelook: What to Verify

Before opening a vial or preparing a patient, practitioners should verify several things.

Product authenticity and integrity. Confirm the product is sourced from an authorized distributor. Check the batch number, manufacturing date, and expiry date on the packaging. Verify that the outer carton, vial seal, and flip-off cap are intact with no signs of tampering. If any element of the packaging is compromised, do not use the product.

Storage conditions. Juvelook is stored at room temperature, protected from direct sunlight. Unlike many injectable aesthetics products, it does not require refrigeration. However, exposure to extreme heat, freezing temperatures, or prolonged direct sunlight may compromise the product. Verify that the product has been stored within the conditions specified on the label throughout the supply chain.

Regulatory status in your market. Juvelook is MFDS-approved and CE-certified but does not hold FDA approval. Before using any injectable product, practitioners must confirm that the product is legally available in their jurisdiction and that they hold the appropriate credentials to administer it under local medical regulations.

The Instructions for Use (IFU). Every Juvelook vial ships with a manufacturer IFU. This document contains the current, product-specific guidance on reconstitution volume, reconstitution method, standing time, injection technique, needle/cannula specifications, treatment areas, contraindications, warnings, and post-treatment instructions. The IFU is the authoritative source for clinical use parameters — not blog articles, social media posts, or third-party training materials. If the IFU has been updated since the practitioner’s last treatment, the updated version takes precedence.

The Professional Use Process: High-Level Overview

The following is a general overview of the clinical workflow for using Juvelook. It is not a replacement for the manufacturer’s IFU or for formal product training. Specific parameters (volumes, depths, techniques, treatment maps) must come from the current IFU and applicable training.

Patient Assessment

As with any injectable treatment, patient assessment comes before product preparation. The practitioner evaluates the patient’s skin condition, treatment goals, medical history, and any contraindications. Juvelook is a skin quality treatment — patients presenting primarily with dynamic wrinkles (expression lines) or deep volume loss may be better served by other product categories (neurotoxins for dynamic wrinkles, volumizing fillers or biostimulators for structural volume).

Patient expectations should be set appropriately: Juvelook results are gradual and cumulative, developing over weeks as new collagen forms. Patients expecting immediate dramatic change should understand the difference between a collagen biostimulator and an HA dermal filler.

Standard pre-treatment considerations apply: reviewing medications that may increase bruising risk (anticoagulants, NSAIDs), identifying allergies, confirming no active infection or skin compromise in the treatment area, and obtaining informed consent.

Product Preparation

Juvelook must be reconstituted before injection. The lyophilized powder is mixed with sterile saline according to the IFU specifications. Key preparation principles include:

Aseptic technique throughout. Reconstitution should be performed in a clean clinical environment with sterile gloves and equipment. The vial septum is swabbed with alcohol before puncture. Only sterile saline (not water for injection, not lidocaine unless specifically authorized by the IFU) should be used for reconstitution.

Follow the specified reconstitution volume. The IFU defines the volume of saline to add. Using too little saline may result in overly concentrated suspension; using too much may dilute the product beyond its effective concentration. The reconstitution volume is not a suggestion — it is a critical product parameter.

Adequate mixing and standing time. After adding saline, the product needs time to fully hydrate. The IFU specifies the mixing method (gentle swirling, not vigorous shaking) and any required standing time. Injecting inadequately reconstituted product increases the risk of complications. Do not rush this step.

Use within the appropriate timeframe. Once reconstituted, Juvelook should be used within the same treatment session. Do not store reconstituted product for later use unless the IFU explicitly permits it with specific storage conditions and maximum holding time.

Injection

Juvelook is injected intradermally — into the dermis, not into muscle and not subcutaneously (for the 50 mg formulation). The needle gauge, injection technique (serial puncture, cross-hatching, or other patterns), injection depth, volume per injection point, and treatment area mapping are all defined in the IFU and refined through product-specific training.

Key technical principles that apply broadly to intradermal injection of particulate biostimulators:

Correct depth matters. Too superficial, and particles may be visible or palpable. Too deep, and the product may not reach the dermal fibroblasts effectively. The practitioner must have anatomical knowledge of dermal thickness in each treatment zone.

Even distribution matters. The goal is uniform delivery of PDLLA microparticles across the treatment area, not concentrated boluses in a few points. Uneven distribution can lead to inconsistent results or localized reactions.

Treatment area suitability. Juvelook 50 mg is designed for skin quality treatment in areas including the face, periorbital zone, neck, and décolletage. The IFU specifies which areas are indicated and which are contraindicated. Areas with very thin skin, mucous membranes, or areas with inadequate subcutaneous support may require particular caution.

Post-Treatment

General post-treatment principles include advising the patient to avoid excessive sun exposure, saunas, intense exercise, and facial massage for a defined period following treatment. The specific post-treatment instructions are detailed in the IFU and should be communicated to the patient both verbally and in written form.

Patients should be informed that the initial mild hydration effect (from the HA component) will diminish within 1 to 2 weeks. The meaningful collagen-building result develops gradually over 4 to 12 weeks. This timeline should be set clearly to avoid patient anxiety about “lost results” in the weeks between the initial post-treatment glow and the onset of collagen remodeling.

Follow-up appointments should be scheduled according to the treatment protocol — typically at approximately 1-month intervals for a course of 3 sessions. The practitioner assesses skin response at each visit and adjusts the treatment plan as clinically indicated.

What the Manufacturer’s IFU Covers — and Why It Is Authoritative

The IFU included with Juvelook covers the full scope of clinical use parameters. Practitioners should treat it as the definitive reference for:

The IFU may be updated by the manufacturer as new data becomes available. Practitioners should ensure they are referencing the version included with the specific batch they are using, not an older version from a previous shipment.

Common Misconceptions About Using Juvelook

“Juvelook is a topical treatment.” It is not. The injectable product is administered by injection into the dermis. (VAIM’s separately branded topical skincare line is a different product category.)

“I can mix it with other products in the same syringe.” Unless the IFU specifically permits co-mixing with another product, do not combine Juvelook with other substances in the same syringe. Mixing products can alter pH, particle size distribution, viscosity, and product behavior.

“More concentrated = better results.” Using less saline than the IFU specifies does not improve results — it changes the product’s particle distribution and may increase complication risk. Follow the specified dilution.

“Any practitioner can use it without training.” While Juvelook does not require the same reconstitution lead time as some biostimulators, it still requires anatomical knowledge, injection technique training, and understanding of intradermal delivery. Product-specific training is recommended.

“Results are instant.” The HA provides mild temporary hydration, but the meaningful clinical result — collagen remodeling — takes weeks to develop. This is by design, not a product limitation.

Product Packaging: What Comes in the Box

Each Juvelook package contains one vial of lyophilized PDLLA + HA powder and a product insert (IFU). The saline for reconstitution, the syringe, and the injection needles are not included — the practitioner supplies these separately from their own medical supplies inventory.

This is standard for many injectable aesthetics products. It also means the practitioner is responsible for selecting appropriate medical-grade syringes and needles that comply with the IFU specifications and local medical device regulations.

Related Guides

• What Is Juvelook? Complete PDLLA + HA Skin Booster Guide
• Juvelook vs Botox: Collagen Stimulator vs Neurotoxin
• Juvelook vs Sculptra: PDLLA vs PLLA Compared
• Juvelook Set and Kit Contents: What’s Included
• Does Juvelook Have Side Effects?

Frequently Asked Questions

Can I use Juvelook at home without a doctor?

No. Juvelook is a Class IV injectable medical device that must be reconstituted and injected by a qualified medical professional using sterile technique. It is not a consumer product and is not available for self-administration.

What supplies do I need that are not in the Juvelook box?

Sterile saline for reconstitution, syringes, and injection needles. The specific gauge and type should follow the manufacturer’s IFU. Topical anesthesia may be applied at the practitioner’s discretion per local protocols.

How many sessions does a full Juvelook treatment require?

The manufacturer recommends 3 sessions at approximately 1-month intervals. The total number of sessions may be adjusted based on clinical response and patient-specific factors, as determined by the treating practitioner.

Can Juvelook be mixed with lidocaine in the same syringe?

Only if the manufacturer’s IFU explicitly permits it. Do not assume that practices used with other injectable products apply to Juvelook. Each product has its own compatibility and reconstitution specifications.

How should reconstituted Juvelook be stored?

Reconstituted Juvelook should be used within the same treatment session unless the IFU specifies otherwise. Do not store reconstituted product for use at a later date without explicit IFU authorization.

Reviewed against publicly available manufacturer information. This article provides a general overview of the professional use framework for Juvelook — not a clinical injection protocol. All specific treatment parameters (reconstitution volume, needle gauge, injection depth, treatment maps, contraindications) must be sourced from the current manufacturer IFU included with the product. Always refer to local regulations regarding injectable medical device administration.

References

1. VAIM Global Inc. Juvelook official product information. juvelook.com
2. Kim J, et al. Poly-d,l-lactic Acid (PDLLA) Application in Dermatology: A Literature Review. Polymers. 2024;16(17):2450.